Stephen R D Johnston

7PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 09, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin

|Oct 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Matthew P Goetz, Erika P Hamilton, Mario Campone

|Jun 27, 2023
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.

Stephen Johnston, Anna Emde, Carlos Barrios

|Jul 29, 2021
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

Harold J Burstein, Mark R Somerfield, Debra L Barton

|Sep 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Stephen R D Johnston, Nadia Harbeck, Roberto Hegg

Pageof 2

Frequent Collaborators

4 joint publications

Miguel Martin

3 joint publications

Nadia Harbeck

3 joint publications

Erika P Hamilton

3 joint publications

Javier Cortes